hector Jesus santana

Dr. hector Jesus santana

Center for Genetic Engineering and Biotechnology
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2013 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
HShector Jesus santana
hector Jesus santana
YGYaima González
Yaima González
PCPatricia Targon Campana
Patricia Targon Campana
JNJesús Noda
Jesús Noda
OAOdalys Amarantes
Odalys Amarantes
RPRolando Páez
Rolando Páez

7 December 2016 in BMC Pharmacology and Toxicology
Verified
Journal Article
Open access
PDF file
IGIdrian García-García
Idrian García-García
IHIgnacio Hernández-González
Ignacio Hernández-González
ADAlina Díaz-Machado
Alina Díaz-Machado
CDCarlos Alberto González Delgado
Carlos Alberto González Delgado
SPSonia Pérez-Rodríguez
Sonia Pérez-Rodríguez
CGCIGB-128-A Study Group
CIGB-128-A Study Group
More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. This could be achieved by combining IFN alpha and IFN gamma. The aim of this work was to characterize the pharmacokinetics and pharmacodynamics of a novel formulation containing a co-formulated combination of IFNs alpha-2b and gamma (CIGB-128-A). A group of nine healthy male subjects received intramuscularly 24.5 × 106 IU of CIGB-128-A. IFN concentrations were evaluated for 48 h. Serum neopterin, beta2-microglobulin (β2M) and 2′–5′ oligoadenylate synthetase (2′–5′ OAS), classical IFN-inducible serum markers, were measured during 192 h by enzyme immunoassay and body temperature was used as pharmacodynamic variable as well. Concerning pharmacokinetics, serum IFNs’ profiles were better fitted to a mono-compartmental model with consecutive zero order and first order absorption, one bioavailability value. No interferences by simultaneous administered IFNs were observed in their typical similar systemic profiles. Neopterin and β2M time profiles showed a delay that was efficiently linked to pharmacokinetics by means of a zero order absorption rate constant. Neopterin level was nine-fold higher than initial values, 48 h post-administration, an increment not described before. At this time, mean serum β2M peaked around the double from baseline. Serum concentrations of the enzyme 2′–5′ OAS was still elevated on the 8 day post-injection. The formulation was well tolerated. Most frequent adverse reactions were fever, headache, arthralgia and lymphopenia, mostly mild. The administration of co-formulated IFN alpha-2b and IFN gamma likely provides improved pharmacodynamic properties that may be beneficial to treat several malignancies. Cuban Public Registry of Clinical Trials RPCEC00000118 , May 24, 2011.

1 November 2014 in Biologicals
Verified
Journal Article
Closed access
HShector Jesus santana
hector Jesus santana
JSJorge Sotolongo
Jorge Sotolongo
YGYaima González
Yaima González
GHGerardo Hernández
Gerardo Hernández
GCGlay Chinea
Glay Chinea
RPRolando Páez
Rolando Páez

15 January 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
LHLídia Ballell i Hosa
Lídia Ballell i Hosa
EGElisabet González-Mira
Elisabet González-Mira
HShector Jesus santana
hector Jesus santana
Judit Morla-FolchJudit Morla-Folch
Judit Morla-Folch
MMMarc Moreno-Masip
Marc Moreno-Masip
Nora VentosaNora Ventosa
Nora Ventosa
Topical delivery has received great attention due to its localized drug delivery, its patient compliance, and its low risk for side effects. Recent developments have focused on studying new drug delivery systems as a strategy for addressing the challenges of current topical treatments. Here we describe the advances on an innovative drug delivery platform called DELOS nanovesicles for topical drug delivery. Previously, the production of DELOS nanovesicles demonstrated potentiality for the topical treatment of complex wounds, achieving well-tolerated liquid dispersions by this route. Here, research efforts have been focused on designing these nanocarriers with the best skin tolerability to be applied even to damaged skin, and on exploring the feasibility of adapting the colloidal dispersions to a more suitable dosage form for topical application. Accordingly, these drug delivery systems have been efficiently evolved to a hydrogel using MethocelTM K4M, presenting proper stability and rheological properties. Further, the integrity of these nanocarriers when being gellified has been confirmed by cryo-transmission electron microscopy and by Förster resonance energy transfer analysis with fluorescent-labeled DELOS nanovesicles, which is a crucial characterization not widely reported in the literature. Additionally, in vitro experiments have shown that recombinant human Epidermal Growth Factor (rhEGF) protein integrated into gellified DELOS nanovesicles exhibits an enhanced bioactivity compared to the liquid form. Therefore, these studies suggest that such a drug delivery system is maintained unaltered when hydrogellified, becoming the DELOS nanovesicles-based hydrogels, an advanced formulation for topical use.

1 October 2017 in Research in Veterinary Science
Verified
Journal Article
Closed access
MVMaribel G. Vallespi
Maribel G. Vallespi
JRJuan C. Rodriguez
Juan C. Rodriguez
LSLilibet Calaña Seoane
Lilibet Calaña Seoane
PAPatricia Alvarez
Patricia Alvarez
HShector Jesus santana
hector Jesus santana
OROsvaldo Reyes
Osvaldo Reyes

1 May 2015 in PDA Journal of Pharmaceutical Science and Technology
Verified
Journal Article
Closed access
PDF file
HShector Jesus santana
hector Jesus santana
GGG. Garcia
G. Garcia
MVM. Vega
M. Vega
ABA. Beldarrain
A. Beldarrain
RPR. Paez
R. Paez
We report on the stability assessment of a recombinant human epidermal growth factor (rhEGF) freeze-dried formulation for wound healing by intra-lesional injections. The suitability of packaging material for the light protection of finished dried powder was evaluated after stressed exposure conditions. Degradation kinetics of powder for injection was investigated at concentrations of 25–250 μg/vial and temperatures of 45, 60, and 70 °C. The long-term stability was evaluated after storage at 25 ± 2 °C/60 ± 5% relative humidity (6 months) and 2–8 °C (24 months) in the dark and analyzed at several time points. The stability after reconstitution with various diluents was also assessed after 24 h storage at 2–8 °C. The rhEGF samples were analyzed for structural integrity by reversed-phase high-performance liquid chromatography (RP-HPLC), size-exclusion HPLC, and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Biological activity was investigated by measuring the cell proliferation in a murine fibroblast cell line. Results show that freeze-dried rhEGF in primary packaging only was photosensitive, as degradation by RP-HPLC that was completely suppressed by the secondary carton package was revealed. An increase in freeze-dried rhEGF stability was observed with the increase in protein concentration from 25 to 250 μg/vial. The long-term stability study showed no significant rhEGF degradation or physical change within the freeze-dried formulations containing 25 or 250 μg/vial of rhEGF. No physical, chemical or biological changes were observed for rhEGF after reconstitution in water for injection or 0.9% sodium chloride during the storage conditions studied.